Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.

RPEP-100042025Asselah, Tarik; Lampertico, Pietro; Aleman, Soo; Bourlière, Marc; Streinu-Cercel, Adrian; Bogomolov, Pavel; Morozov, Viacheslav; Stepanova, Tatiana; Lazar, Stefan; Manuilov, Dmitry; Mercier, Renee-Claude; Tseng, Steve; Ye, Lei; Flaherty, John F; Osinusi, Anu; Da, Ben L; Chee, Grace M; Lau, Audrey H; Brunetto, Maurizia R; Wedemeyer, Heiner

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.

Liver international : official journal of the International Association for the Study of the Liver, 45(4), e16174

View on PubMed ↗Publisher’s paper ↗

Citation

Asselah, Tarik; Lampertico, Pietro; Aleman, Soo; Bourlière, Marc; Streinu-Cercel, Adrian; Bogomolov, Pavel; Morozov, Viacheslav; Stepanova, Tatiana; Lazar, Stefan; Manuilov, Dmitry; Mercier, Renee-Claude; Tseng, Steve; Ye, Lei; Flaherty, John F; Osinusi, Anu; Da, Ben L; Chee, Grace M; Lau, Audrey H; Brunetto, Maurizia R; Wedemeyer, Heiner. (2025). Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.. Liver international : official journal of the International Association for the Study of the Liver, 45(4), e16174. https://doi.org/10.1111/liv.16174